Pieris shares are trading lower after AstraZeneca discontinued Phase 2a trial of Elarekibep for asthma due to disappointing new non-clinical safety findings.
Portfolio Pulse from Benzinga Newsdesk
Pieris Pharmaceuticals' shares are trading lower after AstraZeneca discontinued the Phase 2a trial of Elarekibep for asthma due to disappointing non-clinical safety findings.
June 21, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pieris Pharmaceuticals' stock price is likely to be negatively impacted by AstraZeneca's discontinuation of the Phase 2a trial of Elarekibep for asthma.
The discontinuation of the Phase 2a trial of Elarekibep for asthma by AstraZeneca is a significant setback for Pieris Pharmaceuticals. This news is likely to cause a decrease in investor confidence and negatively impact the stock price of PIRS in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100